Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Cash & Equivalents (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Cash & Equivalents for 7 consecutive years, with $264000.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed 0.38% to $264000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $264000.0 through Dec 2025, changed 0.38% year-over-year, with the annual reading at $264000.0 for FY2025, 0.38% changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $264000.0 at Strata Critical Medical, down from $22.8 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $186.6 million in Q2 2022, with the low at $263000.0 in Q4 2024.
  • Average Cash & Equivalents over 5 years is $27.4 million, with a median of $21.4 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 5998.25% in 2021, then tumbled 94.06% in 2025.
  • Over 5 years, Cash & Equivalents stood at $630000.0 in 2021, then soared by 389.68% to $3.1 million in 2022, then tumbled by 62.79% to $1.1 million in 2023, then crashed by 77.09% to $263000.0 in 2024, then increased by 0.38% to $264000.0 in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $264000.0, $22.8 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.